PFA
LVTX

Pathway Financial Advisors’s LAVA Therapeutics LVTX Stock Holding History

Pathway Financial Advisors’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-102,500
Closed -$135K – 142
2025
Q2 		$135K Hold
102,500
– – 0.02% 132
2025
Q1 		$130K Hold
102,500
– – 0.02% 167
2024
Q4 		$97.5K Hold
102,500
– – 0.02% 162
2024
Q3 		$170K Buy
102,500
+42,500
+71% +$77.8K 0.04% 161
2024
Q2 		$108K Buy
60,000
+46,000
+329% +$121K 0.03% 166
2024
Q1 		$46.6K Buy
+14,000
New +$30.8K 0.01% 172

Other funds holding LVTX

SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Pathway Financial Advisors's LVTX Position: Q3 2025 in Review

Pathway Financial Advisors sold out of LAVA Therapeutics (LVTX) in Q3 2025, closing a stake of 102,500 shares — an estimated $135K sold.

Pathway Financial Advisors first reported a position in LVTX in Q1 2024 and held it in 6 quarters. The position peaked at $170K in Q3 2024. 21 funds tracked by Wall St. Rank hold LVTX as of Q3 2025.

  • Pathway Financial Advisors reported no remaining LAVA Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Pathway Financial Advisors sold 102,500 LAVA Therapeutics shares in Q3 2025, an estimated $135K.
  • Pathway Financial Advisors first reported a position in LAVA Therapeutics in Q1 2024 and held it in 6 quarters.
  • Pathway Financial Advisors's LAVA Therapeutics position peaked at $170K in Q3 2024.
  • 21 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2025.

Based on Pathway Financial Advisors's 13F filing for Q3 2025, filed 10 Oct 2025.